Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAP Targets in Hepatorenal Syndrome
NCT02789150Phase 1Completed
- Sponsor
- University of Louisville
- Start
- Jan 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of norepinephrine in hepatorenal syndrome (HRS) (2 arms), sponsored by University of Louisville. Primary endpoints: Urine Output at 96 hours and Serum Creatinine. Started Jan 2015; status: completed.
02
Drugs
norepinephrine
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT02789150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789150.